Value Adjusted for Debt and Cash: Assertio (ASRT)

Brandmark of Assertio Holdings (ASRT)

Assertio Holdings, Inc. (ASRT) generates revenue through the sale of proprietary therapies for neurological pathologies and pain management. High barriers to entry are driven by patent protection and strict oversight from the FDA and DEA. This price trend reflects an Enterprise Value of 120.55. Stability of supply to pharmacy chains is ensured by specialized transport and precise warehouse inventory accounting.

assertiotx.com - ASRT Total Company Value (period 11/23/2025 - 06/27/2026)

Assertio - analytical breakdowns and key metrics (ASRT)

- stock value and consensus price forecast:
Market Chart Assertio Holdings|ASRT - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Assertio|ASRT - Real Price to Acquire Entire Company
- book capitalization information:
Book Price of a Share Assertio|ASRT - Company Book Value|Capitalization to Book Value Ratio assertiotx.com|ASRT - Company Total Assets
- company total debt and liquidity indicators:
Debt to Capital Assertio Holdings, Inc.|ASRT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Assertio Holdings|ASRT - Company Debts|Debt to Net Assets Ratio Assertio|ASRT - Company Long-Term Debt|Short-Term Debt Assertio|Quick Ratio assertiotx.com
- financial results and valuation multiples details:
ASRT - Company Net Income
Analysis of all company metrics:Assertio Holdings, Inc.
Manufactured product of Assertio

Assertio Holdings, Inc. (ASRT) specializes in bringing therapies for neurological pathologies to market. The enterprise value trend reflects the actual acquisition price of the business by combining market capitalization with net debt. This metric adjusts market expectations by accounting for liabilities and liquid assets. For the scalable distribution model of Assertio Holdings, Inc. (ASRT), such a calculation reveals the efficiency of portfolio expansion without increasing headcount. The final figure determines the company's fundamental resilience to its debt load.

Competitors of Assertio Holdings, Inc. (ASRT)

Company Buyout Price Biogen Inc (BIIB)|NBIX - Total Company Value|Value Adjusted for Debt and Cash RGC (Regencell Corp)|AXSM (Axsome Therapeutics) - Real Price to Acquire Entire Company|ACAD: Aggregate Business Value|Total Company Value Xenon|Business Value VKTX (Viking Therapeutics Inc)|Enterprise Value SUPN|CPRX - Total Enterprise Value|Denali Therapeutics - Real Price to Acquire Entire Company|Enterprise Value harmonybiosciences.com HRMY|BHVN - Total Company Value|Value Adjusted for Debt and Cash AMLX (Amylyx Pharmaceuticals Inc)|Trevi Pharma (TRVI) - Total Company Value|Total Enterprise Value Praxis Corp (PRAX)|AVXL (Anavex Life Sciences) - Enterprise Value|Enterprise Value ceribell.com|Total Company Value Prothena Biosciences (PRTA)|Company Buyout Price alector.com|Total Company Value Annexon Inc. ANNX|Company Buyout Price Omeros Corp (OMER)|Neurogene Inc. - Enterprise Value|Total Enterprise Value acimmune.com|Voyager Therapeutics, Inc. (VYGR) - Total Company Value|Neumora - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company SCLX|TVGN (Tevogen Bio Inc.) - Aggregate Business Value|Enterprise Value ACOG|Company Buyout Price Cognition Therapeutics Inc.|Total Company Value Inhibikase Therapeutics, Inc. IKT|Cassava Sciences Inc (SAVA) - Total Enterprise Value|COYA: Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash VTGN (Vistagen Therapeutics)|OVID: Enterprise Value|acumenpharm.com - Value Adjusted for Debt and Cash|Total Company Value CervoMed|Total Enterprise Value Alterity Therapeutics Ltd ATHE|Total Company Value Clene Inc. (CLNN)|Total Company Value PEPG (pepgen.com)|Enterprise Value JUNS (Jupiter Neurosciences)|RLMD: Business Value|Annovis Bio - Enterprise Value|Company Buyout Price Grace Therapeutics, Inc. GRCE|Firefly Neuroscience Inc (AIFF) - Total Company Value|Business Value KLTO|NRSN (NeuroSense Therapeutics Ltd) - Enterprise Value|RVPH - Full Takeover Company Value|Total Company Value MetaVia Inc (MTVA)|Company Buyout Price NeurAxis Inc.|Helius Medical Technologies - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash PASG|Neuphoria - Enterprise Value|Company Buyout Price minervaneurosciences.com NERV|Athira Pharma (ATHA) - Total Company Value|Business Value ADXN|ALZN (Alzamend Neuro Inc.) - Enterprise Value|Real Price to Acquire Entire Company Cyclerion (CYCN)|Real Price to Acquire Entire Company PTIX (Protagenic Therapeutics)|Company Buyout Price pasitheaclinics.com|Enterprise Value CRGT (Cortigent)|Enterprise Value Avenue Therapeutics Inc. ATXI|BCLI - Total Company Value|Company Buyout Price Cara Therapeutics Inc CARA|Chromocell Therapeutics (CHRO) - Total Company Value|Eliem Therapeutics Inc. - Value Adjusted for Debt and Cash|Real Price to Acquire Entire Company ITCI|LBPH (Longboard Pharmaceuticals Inc) - Aggregate Business Value|Total Company Value Marinus (MRNS)|NKGen Biotech Corp - Business Value|Enterprise Value NRBO (NeuroBo Pharmaceuticals)|sagerx.com (SAGE) - Total Enterprise Value|SNPX: Real Price to Acquire Entire Company|TRVN - Enterprise Value|vigilneuro.com (VIGL) - Total Company Value|anewmeds.com - Value Adjusted for Debt and Cash|Total Company Value Cerevel Therapeutics